Bristol-Myers takes a stake in Taris Biomedical; Zai Lab, Five Prime strike a deal to develop tumor immunotherapy in China
→ Bristol-Myers Squibb has taken a stake in Taris Biomedical as part of their new collaboration on a Phase Ib study of a combo approach …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.